The invention relates to the inhibition of histone deacetylase.
本发明涉及组蛋白脱乙酰基酶的抑制。
The pharmacological actions of histone deacetylase inhibitors and their potential clinic…
综述了组蛋白去乙酰酶抑制剂的药理作用及其临床应用前景。
To reverse the memory loss, doctors inject a compound called a histone deacetylase inhibitor.
为了逆转记忆遗失，医生在复合物中添加了组蛋白脱乙酰基酶抑制物。
The pharmacological actions of histone deacetylase inhibitors and their potential clinical use…
综述了组蛋白去乙酰酶抑制剂的药理作用及其临床应用前景。
SITR1 is a histone deacetylase, a protein that blocks transcription factors from regulating genes.
SITR 1是一种组蛋白脱乙酰基酶，一种能够阻断来自调节基因的转录因子的蛋白质。
Sensitive assay system for inhibitor screening and kinetic assays of HDAC1 (histone deacetylase 1).
一种用于抑制剂筛选和HDAC1动力学检测的敏感检测系统。
The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity.
本发明提供了用于抑制组蛋白脱乙酰基酶酶活性的化合物和方法。
The present invention relates to hydroxamic acid derivatives that are inhibitors of histone deacetylase (HDAC).
本发明涉及作为组蛋白脱乙酰基酶（HDAC）抑制剂的异羟肟酸衍 生物。
Histone deacetylase inhibitors decrease the antigen presenting activity of murine bone marrow derived dendritic cells.
组蛋白去乙酰酶抑制剂降低抗原提呈小鼠骨髓来源的树突状细胞的活性。
Romidepsin is a potent histone deacetylase inhibitor, and is used in the treatment of cutaneous T-cell lymphoma (CTCL).
抗肿瘤药罗米地辛是一种有效的组蛋白去乙酰化酶抑制剂，临床 上用于治疗皮肤T细胞淋巴瘤。
They have discovered an enzyme - histone deacetylase 5 (HDAC5) - has a significant influence on the effect of the hormone.
他们发现，大脑中有一个“开关”控制瘦素的作用，它就是一种名为组蛋白去乙酰化酶5（HDAC5）的酶。
In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors.
认识到开发新颖治疗剂的要求，本发明提供新颖组蛋白去乙酰化酶抑制剂。
ObjectiveTo investigate the antitumor effect of MS275, a histone deacetylase inhibitor, on growth of the human myeloma cell line U266.
目的研究组蛋白去乙酰化酶抑制剂MS275对人多发性骨髓瘤细胞U266增殖的影响。
OBJECTIVE: to investigate the molecular mechanisms of histone deacetylase inhibitor MS-275 on apoptosis of human myeloma U266 cell line.
目的：探讨组蛋白去乙酰化酶抑制剂MS- 275诱导人多发性骨髓瘤细胞株u266凋亡的分子机制。
The researchers found that they could shorten the length of the circadian cycle by removing PSF or SIN3-histone deacetylase complex from mammalian cells.
研究人员经过实验发现，通过去除哺乳动物细胞中的PSF或sin3 -组蛋白去乙酰化酶复合物，他们能够缩短生物钟周期的长度。
Histone deacetylase inhibitors increase the acetylation level of histone as well as some non-histone proteins, and specifically modulate some gene expression.
组蛋白去乙酰酶抑制剂可提高组蛋白的乙酰化水平，并对一些非组蛋白成分产生影响，从而调节某些特定基因的表达。
In this paper, we reviewed the mechanisms on histone acetyltransferases regulating gene transcription and histone deacetylase inhibitors promoting memory formation.
本文主要就组蛋白乙酰转移酶调节基因转录以及组蛋白去乙酰化酶抑制剂促进记忆形成的作用机理进行综述。
The acetylation and deacetylation of histone is charged by a pair of protea se with antistatic function on each other, which are histone transacetylase and histone deacetylase.
组蛋白乙酰化和去乙酰化由一对功能相互拮抗的蛋白酶——组蛋白乙酰基转移酶和组蛋白去乙酰化酶负责。
Purpose: Histone deacetylase inhibitors (HDACi) are being studied in clinical trials with the aim to induce cellular differentiation, growth arrest, and apoptosis of tumor cells.
目的：临床试验中对组蛋白脱乙酰基酶阻滞剂(HDACi)的研究目的在于诱导细胞分化，生长停止，和肿瘤细胞的凋亡。
HDAC and histone deacetylase inhibitors (HDI) can affect expression of some specific genes and induce cell differentiation growth arrest and apoptosis through regulating histone acetylation level.
组蛋白脱乙酰基酶与组蛋白脱乙酰基酶抑制剂通过对组蛋白乙酰化水平的调控，影响特定基因的表达，改变细胞周期的进程。
HDAC and histone deacetylase inhibitors (HDI) can affect expression of some specific genes and induce cell differentiation growth arrest and apoptosis through regulating histone acetylation level.
组蛋白脱乙酰基酶与组蛋白脱乙酰基酶抑制剂通过对组蛋白乙酰化水平的调控，影响特定基因的表达，改变细胞周期的进程。
应用推荐